Zocor, Simvastatin
Zocor, Simvastatin Newswire

Zocor, Simvastatin Newswire

Comprehensive Real-Time News Feed for Zocor, Simvastatin (generic).

Results 1 - 20 of 176 in Zocor, Simvastatin (generic)

  1. Achievement of Dual Low-Density Lipoprotein Cholesteroland...Read the original story

    Tuesday Sep 1 | Circulation

    Background- Statins lower low-density lipoprotein cholesterol and high-sensitivity C-reactive protein ; addition of ezetimibe to statins further reduces LDL-C and hs-CRP. An analysis of the relationship between achieved LDL-C and hs-CRP targets and outcomes for simvastatin and ezetimibe/simvastatin was prespecified in Improved Reduction of Outcomes: Vytorin Efficacy International Trial .

    Comment?

  2. Merck & Co. Release: New Analyses From The IMPROVE-IT Study With...Read the original story

    Monday Aug 31 | BioSpace

    Merck , known as MSD in the United States and Canada, today announced results from new analyses from the IMPROVE-IT study. "IMPROVE-IT presents us with the opportunity to look at cardiovascular outcomes data for patients treated with the combination of simvastatin and ezetimibe and allows us to look at the important aspect of long-term safety and efficacy under controlled conditions" "IMPROVE-IT presents us with the opportunity to look at cardiovascular outcomes data for patients treated with the combination of simvastatin and ezetimibe and allows us to look at the important aspect of long-term safety and efficacy under controlled conditions," said Dr. Michael A. Blazing, Duke Department of Medicine.

    Comment?

  3. Ezetimibe reduces cardiovascular events in diabetics with recent acute coronary syndromeRead the original story w/Photo

    Monday Aug 31 | Medical News Today

    Ezetimibe reduces cardiovascular events in patients with diabetes and a recent acute coronary syndrome, according to a subgroup analysis of the IMPROVE-IT trial presented at ESC Congress by co-principal investigator Dr Robert Giugliano, physician in cardiovascular medicine at Brigham and Women's Hospital in Boston, US. Ezetimibe achieved greater reductions in LDL cholesterol than statins alone, resulting in lower risks of cardiovascular events in patients with diabetes.

    Comment?

  4. Video: Too Many Cholesterol Meds for Elderly Patients?Read the original story w/Photo

    Sunday Aug 30 | ClipSyndicate

    A new study found that statin use in patients age 80 or older without heart disease has increased significantly since 1999. Statins are drugs used to lower cholesterol.

    Comment?

  5. Ezetimibe provides particular benefit in patients with diabetes and recent acute coronary syndromeRead the original story w/Photo

    Saturday Aug 29 | EurekAlert!

    According to the United States Centers for Disease Control and Prevention, over 800,000 Americans die each year from heart disease and stroke. Acute coronary syndrome, which includes heart attack and unstable angina, a condition that can lead to a heart attack, are among the leading causes of death and disability worldwide.

    Comment?

  6. Statin use influences survival after resection for early-stage pancreatic cancerRead the original story

    Thursday Aug 27 | GastroHep.com

    This month's American Journal of Gastroenterology evaluates the impact of statin use on survival in patients undergoing resection for early-stage pancreatic cancer. Dr Bechien Wu and colleagues hypothesized that statin use at baseline would impact survival among patients with early-stage pancreatic cancer, and that the effect might vary by individual statin agent.

    Comment?

  7. Combination Therapy of Metformin and Statin May Decrease...Read the original story

    Tuesday Aug 25 | CiteULike

    Previous studies have shown that metformin or statins may decrease hepatocellular carcinoma in diabetic patients. Accordingly, this article evaluates whether combination therapy may further reduce HCC.

    Comment?

  8. A third of very elderly Americans 'on statins without evidence'Read the original story w/Photo

    Tuesday Aug 25 | Medical News Today

    Statins are being used "without any evidence from testing" among very elderly people in the US, with levels of prescribing rising from 8.8% in 1999-2000 to 34.1% in 2011-2012 for people who have no vascular disease. The oldest age group, over 79 years, have the highest rate of statin use in the US, according to the study published in JAMA Internal Medicine , but this had not been investigated previously.

    Comment?

  9. Is testosterone safe to boost sex drive? - Tue, 25 Aug 2015 PSTRead the original story w/Photo

    Tuesday Aug 25 | The Spokesman-Review

    Q. I love my husband. He is amazing, except for the fact that he hardly ever wants sex.

    Comment?

  10. Primary prevention use of statins increases among the oldest oldRead the original story w/Photo

    Sunday Aug 23 | EurekAlert!

    The use of statins for primary prevention in patients without vascular disease older than 79 increased between 1999 and 2012, although there is little randomized evidence to guide the use of these cholesterol-lowering medications in this patient population, according to a research letter published online by JAMA Internal Medicine . Michael E. Johansen, M.D., M.S., of Ohio State University, Columbus, and Lee A. Green, M.D., M.P.H., of the University of Alberta, Canada, investigated the use of statins among this population by vascular disease because the very elderly have the highest rate of statin use in the United States, according to the study.

    Comment?

  11. Study of Heart and Renal Protection (SHARP): randomized trial to...Read the original story

    Saturday Aug 22 | CiteULike

    Study of Heart and Renal Protection : randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

    Comment?

  12. Merck & Co. Release: New Analyses From The IMPROVE-IT Outcomes Study...Read the original story

    Wednesday Aug 19 | BioSpace

    Merck , known as MSD outside the United States and Canada, announced today that new analyses from the investigational IMPROVE-IT study of VYTORINA , the TECOS cardiovascular safety trial of JANUVIAA , and real-world data from the Dyslipidemia International Study will be presented at the upcoming European Society of Cardiology Congress 2015, held Aug. 29 to Sept. 2, 2015.

    Comment?

  13. New Analyses from the IMPROVE-IT Outcomes Study of VYTORINA ...Read the original story

    Thursday Aug 20 | Freshnews

    Merck , known as MSD outside the United States and Canada, announced today that new analyses from the investigational IMPROVE-IT study of VYTORIN , the TECOS cardiovascular safety trial of JANUVIA , and real-world data from the Dyslipidemia International Study will be presented at the upcoming European Society of Cardiology Congress 2015, held Aug. 29 to Sept. 2, 2015.

    Comment?

  14. Global Dyslipidemia Treatment Market Is Expected to Reach $38 Billion by 2023, Finds New ReportRead the original story w/Photo

    Friday Aug 14 | SBWire

    The global treatment market for dyslipidemia will more than double in value from $15.4 billion in 2013 to an estimated $37.9 billion by 2023, representing a Compound Annual Growth Rate of 9.4%, according to new report. The company's latest report states that the impressive increase, which will occur across the eight major markets of the US, France, Germany, Italy, Spain, UK, Japan, and China, will be driven by the launch of several drugs with blockbuster potential, which are currently in late-stage development, during the forecast period.

    Comment?

  15. Abstract 304: Varicose Vein Development in Mice Is Blocked by Ator-...Read the original story

    Tuesday Aug 11 | Circulation

    Venous diseases such as varicose veins and chronic venous insufficiency constitute a substantial source of morbidity. Despite their high prevalence, neither molecular mechanisms initiating these diseases nor pharmaceutic therapies have been explored so far.

    Comment?

  16. [Editors' Choice] Repurposing statins for Alzheimer's diseaseRead the original story

    Tuesday Aug 11 | Science

    Statins are drugs that inhibit the enzyme HMG-coA reductase in the mevalonate pathway to lower cholesterol and suppress inflammation. Roy et al .

    Comment?

  17. People's Pharmacy: Lotion's acidity neutralizes jalapeno burn - Tue, 11 Aug 2015 PSTRead the original story w/Photo

    Tuesday Aug 11 | The Spokesman-Review

    Q. I de-seeded 15 jalapenos without using gloves, so of course afterward my hands were burning. My daughter-in-law said that her grandfather had always told her to apply "something creamy," so I rubbed on some AmLactin I normally use for dry skin.

    Comment?

  18. Prescription Meds: Too Common in Pregnancy?Read the original story w/Photo

    Monday Aug 10 | KRMG-AM Tulsa

    Aug. 10, 2015 -- Although most doctors say prescribing drugs to pregnant women is a complex issue, they still prescribe them frequently. More than 4 out of 5 moms-to-be were given an Rx for at least one medication, and 42% were prescribed a drug that could harm a developing fetus , researchers found in a large study.

    Comment?

  19. Zhejiang Jingxin Pharmaceutical Co., Ltd (002020) - Financial and Strategic SWOT Analysis ReviewRead the original story

    Monday Aug 10 | PR-inside.com

    Recently published research from GlobalData, "Zhejiang Jingxin Pharmaceutical Co., Ltd - Financial and Strategic SWOT Analysis Review", is now available at Fast Market Research Zhejiang Jingxin Pharmaceutical Co., Ltd is a pharmaceutical company. The company manufactures and markets pharmaceutical products.

    Comment?

  20. Prescription Medications Common in PregnancyRead the original story

    Friday Aug 7 | P&T Community

    More than four out of five pregnant Medicaid recipients were prescribed at least one medication - and 42.0% were prescribed a drug that is potentially harmful to the developing fetus, researchers found in a large, population-based study. According to a Medscape report, the study presents a disturbing pattern.

    Comment?